Overview

A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery

Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
To investigate the efficiency and safety of SOX or SP adjuvant chemotherapy to phase II and III gastric cancer patients after D2 surgery. If SOX is equal to SP in efficiency and less toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
Peking University
Collaborator:
Taiho Pharmaceutical Co., Ltd.
Treatments:
Cisplatin
Oxaliplatin